Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.
The virus spreads easily and quickly through contaminated food and water. Cases often spike each year as people gather with family and friends during the holidays.